Tag: anticoagulation
Bivalirudin vs. Heparin for Maintenance Systemic Anticoagulation During ECMO
When compared with heparin-based systemic anticoagulation, bivalirudin demonstrated feasibility and safety as established by the absence of increases in identifiable adverse outcomes while manifesting substantial improvements... read more
A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children
Using the multicenter Children’s Hospital-Acquired Thrombosis registry, we identified five independent risk factors for hospital-acquired venous thromboembolism in critically ill children, deriving a new hospital-acquired... read more
Anticoagulation in COVID-19
Thrombotic complications (arterial and venous) are common in patients admitted to hospital with COVID-19 and are an independent predictor of poor outcome. Microvascular thrombi also contribute to organ dysfunction, including... read more
Rivaroxaban vs. No Anticoagulation for Post-discharge Thromboprophylaxis After COVID-19 Hospitalisation
In patients at high risk discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days improved clinical outcomes compared with no extended thromboprophylaxis. From Oct 8,... read more
Therapeutic Anticoagulation vs. Usual Care in Noncritically Ill COVID-19 Patients
Among noncritically ill patients with COVID-19 infection, therapeutic anticoagulation with heparin improved the proportion of patients who survived without need for organ support. Therapeutic anticoagulation was associated... read more
COVID-19 and Anticoagulation: Full Dose or Prophylactic Dose?
In CRITICALLY ILL patients with COVID-19, an initial strategy of therapeutic-dose anticoagulation is not associated with a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular... read more
Use of Bivalirudin for Anticoagulation in Pediatric ECMO
This study describes the use of bivalirudin in children on extracorporeal membrane oxygenation (ECMO). Pediatric patients receiving bivalirudin were compared to patients receiving heparin as the anticoagulant on ECMO. Data... read more
Therapeutic vs. Prophylactic Anticoagulation for COVID-19 Patients with Elevated D-dimer Concentration
In patients hospitalised with COVID-19 and elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased... read more
Managing Patients With Short-Term Mechanical Circulatory Support
The use of mechanical circulatory support for patients presenting with cardiogenic shock is rapidly increasing. Currently, there is only limited and conflicting evidence available regarding the role of the Impella (a microaxial,... read more
d-dimer and Death in COVID-19 Patients
In this multicenter cohort study of critically ill adults with COVID-19 admitted to ICUs across the United States, higher d-dimer was independently associated with a greater risk of death. The added value of d-dimer in... read more
Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients
In a cohort of critically ill patients with a high prevalence of thromboembolic events, ET was associated with reduced ICU mortality without an increased burden of haemorrhagic complications. This study suggests ET strategies... read more
Effect of Intermediate-Dose vs. Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, ECMO Treatment, or Mortality Among Patients With COVID-19 in ICU
Among patients admitted to the ICU with COVID-19, intermediate-dose prophylactic anticoagulation, compared with standard-dose prophylactic anticoagulation, did not result in a significant difference in the primary outcome... read more
Surviving Sepsis Campaign Guidelines on the Management of Adults with COVID-19 in the ICU
The Surviving Sepsis Campaign Coronavirus Disease 2019 panel issued several recommendations to guide healthcare professionals caring for adults with critical or severe coronavirus disease 2019 in the ICU. Based on a living... read more
Full-dose blood thinners decreased need for life support and improved outcomes in COVID-19 patients
Full dose anticoagulation (blood thinner) treatments given to patients hospitalized for COVID-19 reduced the requirement of vital organ support in a large clinical trial conducted worldwide. With large numbers of COVID-19... read more
COVID-19 Blood Plasma Trial Finds No Benefit in Severely Ill Patients
An international trial testing convalescent blood plasma on COVID-19 patients with moderate and severe illness has halted enrolment of severely ill COVID-19 patients requiring intensive care after it found no benefit. The... read more
How I Prescribe CRRT
Continuous renal replacement therapy (CRRT) delivers gradual clearance of solutes, fluid balance control, and haemodynamic stability. CRRT does not appear to increase survival compared to intermittent renal replacement therapy... read more
Clinical and Pathophysiologic Aspects of ECMO-associated Hemorrhagic Complications
Extracorporeal membrane oxygenation (ECMO) is increasingly used to treat severe cases of acute respiratory or cardiac failure. Hemorrhagic complications represent one of the most common complications during ECMO, and can... read more
